The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | A real-world analysis of CAR T-cell therapy vs autoSCT in patients with LBCL in complete remission
Rémy Duléry, MD, PhD, Saint-Antoine Hospital, Sorbonne University, Paris, France & Dana Farber Cancer Institute, Boston, MA, discusses an extensive real-world analysis comparing the outcomes of patients with large B-cell lymphoma (LBCL) undergoing autologous stem cell transplantation (autoSCT) or CAR T-cell therapy in complete remission (CR). Dr Duléry highlights that survival rates were comparable between groups and discusses the potential implications of these findings. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
